Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Establishment and application of CHO cell line for producing fucose-free monoclonal antibody

A monoclonal antibody, fucus-free technology, applied in the field of bioengineering, can solve the problems of time-consuming, high cost, cumbersome operation, etc., and achieve the effect of simple operation, low time cost and effective editing

Pending Publication Date: 2017-05-24
SHANGHAI JIAO TONG UNIV +2
View PDF5 Cites 45 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The purpose of the present invention is to overcome the disadvantages of cumbersome operation, long time consumption and high cost in the above-mentioned prior art, and provide a CHO cell line establishment and its application for producing fucose-free monoclonal antibody

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Establishment and application of CHO cell line for producing fucose-free monoclonal antibody
  • Establishment and application of CHO cell line for producing fucose-free monoclonal antibody
  • Establishment and application of CHO cell line for producing fucose-free monoclonal antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0053] This example relates to the establishment and application of a CHO cell line producing a fucose-free monoclonal antibody; its construction process and analysis process are as follows figure 1 , 2 As shown, the specific steps are as follows:

[0054] 1: Construction of FUT8 knockout vector PX330-sgRNA plasmid

[0055] From the protein sequence (NCBI: XP_003501783.1, SEQ ID NO.12) corresponding to the FUT8 gene (its mRNA sequence (CHO-WT) is shown in SEQ ID NO.1), it can be seen that the amino acid position corresponding to exon9 has The function is the binding site of GDP-fucose, which can transfer GDP-fucose to the N-acetylglucosamine core site of the expressed protein. If the gene sequence is mutated, the function of α-1,6 fucosyltransferase can be lost.

[0056] The pX330 plasmid contains human codon-optimized streptococcal hspCas9 endonuclease coding sequence and U6 RNA polymerase promoter sequence. The schematic diagram of the partial structure of the plasmid is...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses establishment and application of a CHO cell line for producing a fucose-free monoclonal antibody. A CRISPR / Cas9 technology is utilized to encode an FUT8 gene of a CHO cell to obtain the FUT8 gene silenced CHO cell line for stabilizing FUT8 gene deletion (hereinafter referred to as FUT8- / -cell line). By adopting physicochemical property and bioactivity detection of an FUT8- / -cell expressed antibody, a glycoform detection result indicates that fucose of the FUT8- / -cell expressed monoclonal antibody is completely eliminated, a fucose-containing monoclonal antibody expressed by a wild CHO cell serves as a contrast, the affinity with a Fcgamma RIIIa antigen of the fucose-free monoclonal antibody is improved by 7 times, and the ADCC effect is improved by 25 times.

Description

technical field [0001] The invention belongs to the technical field of bioengineering, and specifically relates to the establishment and application of a CHO cell line for producing fucose-free monoclonal antibodies. Background technique [0002] The initial use of antibodies in disease treatment can be traced back a century ago, but its rapid development was mainly in the past 30 years. In 1975, Koehler and Milstein founded the in vitro hybridoma technology, obtained mouse-derived monoclonal antibodies, and started a new era of polyclonal antibodies moving towards monoclonal antibodies (Wang Zhiming, Gao Jian and Li Geng, Therapeutic monoclonal antibody drugs Current situation and development trend. China Biotechnology Journal, 2013(06): p.117-124). Monoclonal antibodies have the advantages of high specificity, high titer, high purity, strong reproducibility, low cost, and mass production. However, the application of mouse-derived monoclonal antibodies to humans has strong...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/85C12N15/113C12N5/10C07K16/44
CPCC07K16/44C07K2317/51C07K2317/515C12N15/113C12N15/85C12N2310/10C12N2800/107
Inventor 朱建伟宗会芳张宝红江华谢跃庆韩雷丁凯孙涛
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com